Ensysce Biosciences (ENSC) Change in Account Payables (2020 - 2025)
Ensysce Biosciences (ENSC) posted quarterly Change in Account Payables of -$579374.0 for Q3 2025, down 133.34% year-over-year from $1.7 million in Q3 2024, and down 235.51% quarter-over-quarter from $427537.0 in Q2 2025.
Ensysce Biosciences (ENSC) Change in Account Payables (2020 - 2025) Analysis & Trends
Ensysce Biosciences (ENSC) has reported Change in Account Payables for 6 consecutive years, with -$579374.0 the latest figure, recorded in Q3 2025.
- In Q3 2025, Change in Account Payables fell 133.34% year-over-year to -$579374.0; the TTM figure through Sep 2025 stood at -$1.4 million (down 292.39% YoY), while the FY2024 annual figure was -$578928.0, up 53.1% from the prior year.
- Change in Account Payables retreated to -$579374.0 in Q3 2025 per ENSC's latest filing, from $427537.0 in the prior quarter.
- Across five years, Change in Account Payables topped out at $2.1 million in Q2 2022 and bottomed at -$1.8 million in Q3 2022.
- Historically, Change in Account Payables has averaged -$78297.1 across 5 years, with a median of -$323538.0 in 2023.
- Annual changes were most pronounced in 2021 — Change in Account Payables tumbled 865.92% — and 2022, when it jumped 1071.15%.
- Ensysce Biosciences' Change in Account Payables stood at -$170754.0 in 2021, then surged by 1071.15% to $1.7 million in 2022, then slumped by 52.17% to $793088.0 in 2023, then plunged by 165.73% to -$521262.0 in 2024, then fell by 11.15% to -$579374.0 in 2025.
- Business Quant data shows ENSC's Change in Account Payables at -$579374.0 in Q3 2025, $427537.0 in Q2 2025, and -$741784.0 in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Account Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | -66.70 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -8.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 37.53 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Ensysce Biosciences | 942,649.19 | -3.37 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | -579,374.00 |
| Sep 30, 2025 | -579,374.00 |
| Jun 30, 2025 | 427,537.00 |
| Jun 30, 2025 | 427,537.00 |
| Mar 31, 2025 | -741,784.00 |
| Mar 31, 2025 | -741,784.00 |
| Dec 31, 2024 | -521,262.00 |
| Dec 31, 2024 | -521,262.00 |
| Sep 30, 2024 | 1.74 Mn |
| Sep 30, 2024 | 1.74 Mn |
| Jun 30, 2024 | -499,749.00 |
| Jun 30, 2024 | -499,749.00 |
| Mar 31, 2024 | -1.30 Mn |
| Mar 31, 2024 | -1.30 Mn |
| Dec 31, 2023 | 793,088.00 |
| Dec 31, 2023 | 793,088.00 |
| Sep 30, 2023 | -358,213.00 |
| Sep 30, 2023 | -358,213.00 |
| Jun 30, 2023 | -323,538.00 |
| Jun 30, 2023 | -323,538.00 |